Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026
SEATTLE, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced updated interim monotherapy results from its ongoing Phase 1/2a clinical trial of [ 212 Pb]lapemelanotide zapixetar (VMT01), an investigational targeted alpha therapy. The Company presented the data as a poster at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, being held November 4 to 8, 2026, in Phoenix, Arizona.